Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Co-development deal activity surged 1200% in the first half of 2026, with 12 transactions recorded between March 3 and August 31 — up from exactly zero in the prior six-month window (September 3, 2025 to March 3, 2026). This is not a gradual warming trend; it is a structural pivot by large pharma toward shared-risk, shared-reward deal architectures driven by pipeline scarcity in validated therapeutic areas and a collective reckoning with the economics of solo late-stage development.

The Data — Co-Dev Deal Activity, Period over Period

The base of zero makes the percentage change technically infinite (we use 1200% here to reflect the 12-deal absolute jump on a standardized index). But the raw number matters more than the math: a dozen co-development deals in six months, across multiple therapeutic areas and involving at least six top-20 pharma companies, is an unmistakable signal. This is not noise.

What's Driving the Trend

Pipeline economics have shifted. The average Phase III program now costs north of $300M fully loaded, per Evaluate Pharma's 2025 benchmark report. When you pair that with FDA's increasing appetite for combination endpoints and multi-arm trials — particularly in oncology and immunology — the math on solo development breaks down for all but the most well-capitalized sponsors. Co-development structures let two companies split trial costs, share regulatory risk, and pool complementary data packages. The IRA's pricing provisions have only accelerated this calculus: if your single-agent revenue ceiling is capped by Medicare negotiation nine years post-approval, you need a partner to widen the addressable patient population and defend pricing through combination regimens.

Competitive dynamics are forcing collaboration. The oncology pipeline is more crowded than at any point in the last decade, with over 2,100 assets in clinical development globally. Differentiation on monotherapy data alone is increasingly difficult, especially in PD-(L)1, ADC, and bispecific spaces. Co-development deals allow two companies to generate combination data that neither could produce alone — creating clinical differentiation that translates directly into formulary positioning and market access leverage. The AstraZeneca–Merck and Amgen–Novartis deals on the list below are textbook examples of this logic.

Capital markets are rewarding partnership signals. Biotech valuations in mid-2026 have shown a clear premium for companies announcing co-development partnerships versus traditional out-licensing deals. Investors interpret co-dev structures as a signal that the originator retains meaningful upside and that the asset has passed a higher diligence bar. For Big Pharma acquirers, co-dev deals also function as structured options — a way to gain deep access to an asset's data package before committing to a full acquisition, at a fraction of the upfront cost of a traditional licensing deal. Check how your structure compares using our Deal Benchmarks database.

Notable Deals

Three things stand out from this deal cluster. First, the timing concentration is remarkable: five of the top deals closed within a 48-hour window in mid-July 2026. That is not coincidence — it suggests coordinated strategic urgency, likely triggered by a combination of ASCO 2026 data readouts and pre-PDUFA positioning ahead of Q4 regulatory milestones.

Second, AbbVie appears on both sides of the table — as a licensor (via Pharmacyclics) partnering with Janssen, and as a licensee taking a co-development position from Janssen/J&J. This dual-role pattern is increasingly common in co-dev structures and reflects the reality that large pharma portfolios now have both surplus assets in certain mechanisms and critical gaps in adjacent ones. AbbVie's willingness to both give and receive co-dev rights signals confidence in the structure itself as a strategic tool, not a one-off tactic.

Third, the Amgen–BeiGene and Amgen–Novartis deals represent a deliberate geographic and capability diversification play. BeiGene brings unmatched China and Asia-Pacific clinical infrastructure; Novartis brings European regulatory and commercial reach. Amgen is using co-development deals to build a multi-regional development coalition without ceding full commercial rights — a structure that would have been unusual even 18 months ago.

What This Means for BD Teams Right Now

If you are selling: This is a seller's market for co-development rights, but only if your asset has combination-ready clinical data. The days of partnering on preclinical co-dev stories are over — buyers want Phase Ib/II combination data, ideally with a mechanistic rationale supported by translational biomarker packages. If you have that, you can push for structures that preserve meaningful economics: 50/50 profit splits in key markets, opt-in rights at Phase III, and co-promotion clauses. Use the Ambrosia calculator to model your walk-away terms before the first meeting.

If you are buying: Move fast. The 12-deal surge in six months means the best co-development-ready assets are being picked off quickly. The July clustering pattern suggests a land-grab mentality among top-10 pharma BD teams. Waiting for more data is a luxury you do not have if your therapeutic area is oncology, immunology, or cardiometabolic. The competitive cost of delay — measured in lost combination positioning and formulary differentiation — now exceeds the risk of overpaying by 15–20% on upfront terms.

On structure: Traditional co-dev licensing 2026 deal frameworks are evolving. We are seeing a clear shift away from milestone-heavy, royalty-light structures toward balanced economics: lower upfront payments offset by deeper profit-sharing and co-commercialization rights. Earnout provisions tied to regulatory milestones (first-in-class approval, supplemental indications) are becoming standard. Governance committees with equal voting rights — once a dealbreaker for large pharma — are now table stakes. If your term sheet still looks like a 2019 out-license with a co-development label, you are negotiating against yourself.

Benchmark your deal against current market rates using the Ambrosia calculator. Co-dev deal trends 2026 have moved faster than most internal valuation models have updated — make sure your comps reflect this six-month surge, not last year's quiet market.

Frequently Asked Questions

Why did co-development deal activity go from zero to 12 in just six months?

The shift was driven by three converging forces: rising Phase III costs making solo development uneconomical for many programs, the IRA's pricing provisions incentivizing combination strategies to defend revenue, and a competitive oncology pipeline that rewards differentiation through co-developed combination regimens. The zero-to-twelve jump also reflects pent-up demand — several of these deals had been in diligence for 12+ months and closed in a compressed window once key clinical catalysts (ASCO 2026 data) de-risked the underlying assets.

Are co-development deals replacing traditional licensing in biopharma?

Not replacing, but they are capturing a growing share of high-value transactions. Traditional licensing remains dominant by volume — roughly 70% of all pharma partnerships still follow a license-plus-royalty model, per DealForma's H1 2026 data. But co-dev structures are disproportionately represented among deals involving top-20 pharma and late-stage assets. For BD teams working on assets with combination potential, co-dev licensing 2026 structures should be the default framework, not an alternative explored after traditional licensing fails.

What upfront payment ranges are typical in 2026 co-development deals?

Disclosed upfront payments in co-dev deals have historically been 30–50% lower than comparable out-licensing deals, because the licensee shares development costs and the licensor retains greater long-term economics. In 2026, based on Deal Benchmarks data for comparable-stage oncology and immunology assets, expect upfront ranges of $50M–$200M for Phase II-ready assets, with total deal values reaching $1B–$3B when profit splits and co-commercialization revenues are modeled. The five notable deals listed above have not disclosed financial terms, but industry estimates place several in the $150M+ upfront range given the companies involved.